Unique advantage of Janus kinase 3 as a target for selective and nontoxic immunosuppression.

Stepkowski SM, Kirken RA. Unique advantage of Janus kinase 3 as a target for selective and nontoxic immunosuppression. Expert Rev Clin Immunol. 2005 Sep; 1(3):307-10.

View in: PubMed

authors with profiles

Robert Kirken

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support